Among the numerous interleukins developed for tumor therapy, IL-2, initially called T cell growth factor, holds a significant place as it was the first to receive approval from the U.S. Food and Drug Administration for the treatment of metastatic melanoma and renal cell carcinoma.8 Here, IL2 is linked to neoplasm.